The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dual TGF-β and AURKA targeting enhances chemosensitivity in triple-negative breast cancer.
 
Fahad Ahmed Faruqi
No Relationships to Disclose
 
Mohammad Jalalirad
No Relationships to Disclose
 
Antonino Bonaventura D'Assoro
No Relationships to Disclose
 
Tufia C. Haddad
Consulting or Advisory Role - Tersera
Research Funding - Takeda (Inst)
 
Jodi M Carter
No Relationships to Disclose
 
Judy Caroline Boughey
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - METHODS AND MATERIALS FOR ASSESSING CHEMOTHERAPY RESPONSIVENESS AND TREATING CANCER (Inst)
 
Leiwei Wang
No Relationships to Disclose
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Context Therapeutics; Eisai; Genomic Health; Lilly; Novartis; Pfizer; Sermonix Pharmaceuticals
Research Funding - Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
Travel, Accommodations, Expenses - Lilly
 
James N. Ingle
No Relationships to Disclose